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Background: The thicker strut of metallic stents potentially contributes to a higher incidence of side branch occlusion (SBO). This study sought to assess the incidence and clinical impact of SBO after bioresorbable vascular scaffold (BVS) implantation in percutaneous CTO revascularization. Methods: 35 consecutive true CTOs lesions (Euro-CTO club definition) treated with BVS were included in this prospective study. Target lesions were scaffold after mandatory pre-dilatation and IVUS analysis. Side branch occlusion (SBO) was defined as a reduction in TIMI flow to grade 0 or 1. Accordingly, side branches (SB) with pre-BVS implantation TIMI flow grade 0 or 1 were excluded. Visible SB were classified in two groups: really small (< 0.5mm) or not (! 0.5mm).
Results:
The most frequent lesions treated were the RCA (46%) and LAD (40%). According to the Japanese-CTO score of complexity most of lesions were classified as intermediate (49%) or difficult-very difficult (26%). 34% were moderate-severe calcified lesions. Pre-dilatation was 100% by cutting balloon in 71%. The total scaffold length implanted per lesion was of 52.5 AE 22.9mm. All the scaffolds were delivery and deployment successfully. Post-dilatation was done in 63%. The total number of visible SB covered by BVS was 109 (3.2 AE 1.4 per lesion). SBO after BVS implantation was described in (7/109) 6.4%. Really small SB (SB< 0.5mm), were slightly more frequently occluded (4) 3.7% compared to SB !0.5mm (3) 2.8%. In 4 of 7 of cases of SBO, a significant dissection after balloon dilatation and before BVS implantation was observed. However, dissection was reported in 1/4 (25%) of really small SB and in 3/3 (100%) of bigger SB !0.5mm. Post-procedural SBO was not related with an increased incidence of in-hospital myocardial infarction. At a median of 10.2 (6.2-11.9) months, no MACE was reported and all the devices were patent by MSCT. Conclusions: In our study with long complex lesions covered by BVS we report a relatively slow rate of SBO after BVS implantation, including all visible SB. Moreover it seemed that SBO had not a significant impact in in-hospital or midterm adverse events. Further investigation is required in a pivotal randomized trial.
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Dissection and re-entry techniques and longer-term outcomes following successful percutaneous coronary intervention of chronic total occlusion Background: New techniques involving dissection of the sub-intimal space and reentry into the true lumen increase success rates. However, their long-term safety and efficacy is unknown. Methods: We assessed the impact of dissection-re-entry techniques and sub-intimal drug-eluting stent (DES) implantation on longer-term outcomes following successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI). This study included a series of consecutive patients who underwent CTO PCI between 01/2010 and 01/2013. Events were collected if patients were re-admitted. If not, they were contacted 12-18 months after their PCI. The combined incidence of cardiac death, myocardial infarction, ischemia-driven target vessel revascularisation (TVR) or reocclusion was evaluated as our primary outcome. Results: Out of 212 CTOs treated, 192 (91%) were successfully opened (in 179 patients). Follow-up data was available for 187 CTOs (97.4%), with 82 (44%) that were opened with dissection-re-entry, and 105 (56%) with wire escalation techniques. No patient died from cardiac causes. At a median follow-up of 398 days, the primary outcome occurred in 18/179 CTOs treated (10.7%), driven by TVR. Eleven CTOs (15.2 %) treated with dissection-re-entry vs. 7 CTOs (7.3%) treated with wire escalation presented with the primary outcome (p¼0.17). With multivariate adjustment, dissection-re-entry techniques had no significant impact on outcomes. However, treatment of an in-stent occlusion was independently associated with the primary outcome (HR>6.0; p< 0.001).
Conclusions: Conclusion: Dissection-re-entry techniques have minimal impact on longer-term outcomes following CTO PCI, which are favorable in the majority of patients. However, treatment of an in-stent occlusion was a predictor of subsequent adverse outcomes.
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Incidence 124 AE 68 min, respectively; p¼0.003) with a greater use of contrast load (470 AE 193 ml vs.436 AE 227 ml, respectively; p¼0.04) and higher number of stents (3.1 AE 1.5 vs. 2.9 AE 1.4, respectively; p¼0.035). Coronary perforation were more often observed in BFLs (4.9% vs. 1.7%; p< 0.001) resulting in more tamponades (2.4% vs. 0.2%; p< 0.001). True BFLs were encountered in the majority of cases (86.8%) and required more 2-stent technique than false BFLs (50% vs. 18.8%; p¼0.001).
Conclusions: The incidence of BFLs in CTO lesions is higher than generally reported in continuous coronary artery disease patients. The presence of BFLs in a CTO vessel remains a challenging situation for interventional cardiologists that increases the complexity of CTO procedure and may lead to less angiographic success and more peri-procedural complications.
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Subintimal laser atherectomy for chronic total occlusion revascularization Background: Laser atherectomy is useful for debulking coronary lesions, but can cause perforations. While lasers have been used to break down the proximal cap of chronic total occlusions (CTO) and help create microchannels through non-crossable lesions, using laser in the extraluminal space has been previously prohibited. Methods: A retrospective case series was performed of patients who underwent CTO revascularization using subintimal laser atherectomy with a 0.9 mm laser catheter. Patients with antegrade subintimal dissection reentry and reverse controlled antegraderetrograde dissection (reverse CART) were included. In all cases the laser was advanced antegrade in the target vessel. Clinical and procedural characteristics, and outcomes at hospital discharge were collected.
Results: Eleven patients underwent revascularization using laser atherectomy in the subintimal space. The average J-CTO score was 3 AE 0.2 and lesion length 69.5 AE 11.0 cm. 
